TY - JOUR
T1 - Routine Ophthalmological Examination Rates in Adults with Sickle Cell Disease Are Low and Must Be Improved
AU - Zulueta, Patricia
AU - Minniti, Caterina P.
AU - Rai, Anvit
AU - Toribio, Tiana J.
AU - Moon, Jee Young
AU - Mian, Umar K.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.
AB - The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.
KW - screening
KW - sickle cell disease
KW - sickle cell retinopathy
UR - http://www.scopus.com/inward/record.url?scp=85148964639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148964639&partnerID=8YFLogxK
U2 - 10.3390/ijerph20043451
DO - 10.3390/ijerph20043451
M3 - Article
C2 - 36834146
AN - SCOPUS:85148964639
SN - 1661-7827
VL - 20
JO - International journal of environmental research and public health
JF - International journal of environmental research and public health
IS - 4
M1 - 3451
ER -